Skip to main content
Premium Trial:

Request an Annual Quote

NHGRI Seeks to Establish Mouse Genome Network

Premium

Bethesda, Md.--The National Human Genome Research Institute is seeking to establish a mouse genome sequencing network that will support mapping and sequencing the mouse genome. Late last month, the institute published a request for applications entitled "Network for Large-Scale Sequencing of the Mouse Genome." The network will generate the necessary mapping resources and begin production of a working draft of the DNA sequence of the mouse genome, the institute said.

Applications for both pilot sequencing in new groups and expansion of the capacity of existing sequencing centers are being encouraged. The long-term goal of the network will be to complete a high-quality DNA sequence of the mouse genome in cooperation with the international mouse research community. A total of $21 million per year is available for funding through grants ranging from one to three years. Additional information is available at http://www.nih. gov/grants/guide/rfa-files/RFA-HG-99-001.html.

Filed under

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.